When was SiteOne Therapeutics founded?

SiteOne Therapeutics was founded in 2010 and raised its 1st funding round 2 years after it was founded.

Where is SiteOne Therapeutics located?

SiteOne Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of SiteOne Therapeutics?

John V. Mulcahy of SiteOne Therapeutics. They have also founded 1 company.

How many employees does SiteOne Therapeutics have?

As of Jun 30, 2026, the latest employee count at SiteOne Therapeutics is 1.

Is SiteOne Therapeutics a funded company?

SiteOne Therapeutics is a funded company, having raised a total of $124M across 15 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Dec 15, 2012.

How much is SiteOne Therapeutics worth?

The last known valuation of SiteOne Therapeutics was $***** as of May 27, 2025.

When was the latest funding round of SiteOne Therapeutics?

SiteOne Therapeutics' latest funding was a $***** Grant (prize money) round on Apr 28, 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.05B in funding in 2026 to date.

Where does SiteOne Therapeutics rank among its competitors?

SiteOne Therapeutics ranks 1085th amongst 2784 active competitors, of which 915 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of SiteOne Therapeutics?

SiteOne Therapeutics' top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

SiteOne Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Q: Is SiteOne Therapeutics an acquired company?

SiteOne Therapeutics got acquired by Lilly on May 27, 2025.

SiteOne Therapeutics is an acquired company based in San Francisco (United States), founded in 2010 by John V. Mulcahy. It operates as a Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain.. SiteOne Therapeutics has raised $124M in funding from investors like Amgen, Sears Capital Management and Mission Bay Capital, with last known valuation of $*****. The company has 2784 active competitors, including 915 funded and 697 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.

Company Details

SiteOne Therapeutics is focussed on developing pain therapeutics for the treatment of acute and chronic pain. Its therapeutic candidates are selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Its lead product for the treatment of moderate to severe pain is in pre-clinical trials Its technology also has additional applications in long-acting analgesics, PET imaging diagnostics for pain and other pain indications.

Website: siteonetherapeutics.com
Email ID: *****@site1therapeutics.com

Key Metrics

Founded Year

2010

Location

San Francisco, United States

Stage

Acquired

Total Funding

$124M in 15 rounds

Latest Funding Round

Grant (prize money), Apr 28, 2025, $*****

Last Known Valuation

$***** as on May 27, 2025

Investors

Amgen & 14 more

Ranked

1085^th among 2784 active competitors

Employee Count

1 as on Jun 30, 2026

Similar Companies

Heron Therapeutics & 325 more

Exit Details

Acquired by Lilly (May 27, 2025)

View SiteOne Therapeutics' full profile

SiteOne Therapeutics got acquired by Lilly on May 27, 2025 at an acquisition amount of $*****.

Click here to take a look at SiteOne Therapeutics's acquisition in detail

SiteOne Therapeutics has raised a total funding of $124M over 15 rounds. Its first funding round was on Dec 15, 2012. Its latest funding round was a Grant (prize money) round on Apr 28, 2025 for $*****. 1 investor participated in its latest round. SiteOne Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of SiteOne Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2025	4071081	Grant (prize money)	4311212	7414704	6819641	1834047
Dec 18, 2024	6578546	Series C	4836830	2425888	3132376	Orbimed & 3 more
Mar 29, 2024	4439968	Series B	3633734	5737543	9348133	7354454

Access funding benchmarks and valuations. Sign up today!

View details of SiteOne Therapeutics's funding rounds and investors

The founders of SiteOne Therapeutics is John V. Mulcahy. John V. Mulcahy is the CEO of SiteOne Therapeutics.

Here are the details of SiteOne Therapeutics' key team members:

John V. Mulcahy: Co-Founder & CEO of SiteOne Therapeutics.

View details of SiteOne Therapeutics's Founder profiles and Board Members

SiteOne Therapeutics' employee count trend

SiteOne Therapeutics has 1 employees as of Jun 26. Here is SiteOne Therapeutics's employee count trend over the years:

Employee count trend for SiteOne Therapeutics

Uncover SiteOne Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SiteOne Therapeutics include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of SiteOne Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
1085th	SiteOne Therapeutics 2010, San Francisco (United States), Acquired	Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain.	$124M	BioBrit, Wellington & 13 others	36/100